Henlius Raises Stakes In Denosumab Race With Phase I Completion
HLX14 Denosumab Biosimilar Scores PK Trial Win; Submissions Expected Later This Year
Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.
